Aortic Stenosis Market Report 2026

The aortic stenosis market size has grown rapidly in recent years. It will grow from $8.91 billion in 2025 to $10.06 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to aging global population, increasing prevalence of degenerative heart valve diseases, expansion of cardiac catheterization labs, improvements in surgical valve replacement techniques, rising clinical awareness of valvular disorders.

The aortic stenosis market size is expected to see rapid growth in the next few years. It will grow to $16.17 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing investments in next-generation valve technologies, rising adoption of tavr procedures, expansion of outpatient cardiac care models, growing focus on early intervention strategies, increasing integration of digital cardiac monitoring tools. Major trends in the forecast period include increasing adoption of transcatheter valve replacement procedures, rising demand for minimally invasive cardiac interventions, growing use of advanced diagnostic imaging, expansion of personalized valve therapy solutions, enhanced focus on early disease detection.

The rising prevalence of heart diseases is expected to drive the growth of the aortic stenosis market in the coming years. Heart diseases encompass a variety of conditions that affect the structure and function of the heart. These conditions can impair the heart's ability to pump blood efficiently, resulting in complications. Common heart diseases include coronary artery disease (CAD), heart failure, arrhythmias, valvular heart disease, cardiomyopathy, and others. Aortic stenosis is characterized by the narrowing of the aortic valve, which restricts blood flow from the left ventricle to the aorta. This increased resistance forces the heart to work harder, potentially causing heart failure and other cardiovascular complications over time. Appropriate treatment of aortic stenosis, such as valve replacement or TAVI, helps enhance heart function and reduces the risk of severe heart disease outcomes. For example, in January 2025, according to the British Heart Foundation, a UK-based cardiovascular research charity, around 7.6 million people in the UK are living with heart and circulatory diseases, including approximately 4 million males and 3.6 million females. These conditions account for about 27% of all deaths in the UK, resulting in over 170,000 fatalities annually, or roughly 480 deaths per day. Consequently, the increasing prevalence of heart diseases is fueling the growth of the aortic stenosis market.

Major companies operating in the aortic stenosis market are concentrating on developing advanced aortic valve technologies, including transcatheter aortic valve implantation (TAVI) systems, to enhance patient outcomes, minimize procedural risks, and improve the overall effectiveness of aortic treatment. The transcatheter aortic valve implantation (TAVI) system is a minimally invasive medical device that can replace a damaged aortic valve without the need for open-heart surgery. For example, in January 2023, Abbott Laboratories, a US-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for Navitor, a latest-generation transcatheter aortic valve implantation (TAVI) system. Navitor incorporates the NaviSeal fabric cuff to reduce or prevent paravalvular leaks. Its design, with leaflets positioned within the native valve, is intended to improve access to coronary arteries for potential future treatments of coronary artery disease.

In August 2024, Edwards Lifesciences, a US-based heart valve technologies company, acquired JC Medical for an undisclosed amount. Through this acquisition, Edwards Lifesciences strengthens its structural heart portfolio by incorporating the J-Valve system, a transcatheter aortic valve replacement (TAVR) technology used for treating severe aortic regurgitation. JC Medical is a US-based medical device company focused on developing transcatheter aortic valve implantation (TAVI) systems to address both aortic stenosis (AS) and aortic regurgitation (AR).

Major companies operating in the aortic stenosis market are Abbott Laboratories, Medtronic plc, Edwards Lifesciences Corporation, Boston Scientific Corporation, Terumo Corporation, LivaNova PLC, CryoLife Inc, Anteris Technologies Ltd, Venus Medtech, Peijia Medical, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, Symetis SA, Artivion Inc, HighLife SAS, Transcatheter Technologies GmbH, NaviGate Cardiac Structures Inc, Xeltis BV, Sorin Group, Meril Life Sciences Pvt Ltd, On-X Life Technologies Inc, Braile Biomédica, Colibri Heart Valve.

North America was the largest region in the aortic stenosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aortic stenosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aortic stenosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the aortic stenosis market by increasing costs of imported transcatheter valves, surgical implants, delivery systems, imaging equipment, and precision manufacturing components. Cardiology centers and hospitals in North America and Europe are most affected due to reliance on imported high-value cardiac devices, while Asia-Pacific faces increased costs in device manufacturing and distribution. These tariffs are raising procedure costs and impacting adoption rates. However, they are also supporting local valve manufacturing initiatives, regional device innovation, and investments in domestic cardiovascular technology development.

The aortic stenosis market research report is one of a series of new reports that provides aortic stenosis market statistics, including aortic stenosis industry global market size, regional shares, competitors with a aortic stenosis market share, detailed aortic stenosis market segments, market trends and opportunities, and any further data you may need to thrive in the aortic stenosis industry. This aortic stenosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aortic stenosis is a condition in which the aortic valve in the heart narrows, limiting blood flow from the left ventricle to the aorta and the rest of the body. It is commonly caused by age-related valve calcification, congenital valve abnormalities, or rheumatic fever. Aortic stenosis may result in serious complications like heart failure, which can be managed with medications or surgical procedures such as valve replacement.

The primary forms of aortic stenosis include congenital aortic stenosis and acquired aortic stenosis. Congenital aortic stenosis is characterized by a narrowing of the aortic valve present from birth, which limits blood flow from the heart's left ventricle to the aorta. Treatment options consist of surgical aortic valve replacement, transcatheter aortic valve replacement, and balloon aortic valvuloplasty. These treatments are delivered through different methods, including oral, parenteral, and implantable approaches. Distribution channels are divided into offline and online platforms, while end users include hospital pharmacies, retail pharmacies, and online pharmacies.

The aortic stenosis market consists of revenues earned by entities by providing services such as surgical treatments, transcatheter aortic valve replacement, balloon valvuloplasty and medical management. The market value includes the value of related goods sold by the service provider or included within the service offering. The aortic stenosis market includes sales of medical devices, diagnostic and monitoring tools and surgical instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.